Summary of Tocagen Inc. and Forte Biosciences Merger Conference Call Company Overview - **Companies Involved**: Tocagen Inc. (TOCA) and Forte Biosciences - **Date of Call**: February 20, 2020 Key Points from the Conference Call Merger Announcement - Tocagen and Forte have agreed to merge, creating a dermatology-focused company with a lead asset, FB-401, for atopic dermatitis [6][8] - The merger follows Tocagen's strategic review after disappointing Phase 3 results in September 2019 [6] Financial Structure - Tocagen's equity holders are expected to own approximately 25.5% of the combined company, while Forte's equity holders will own 74.5% on a fully diluted basis [7] - The combined company is projected to have a cash balance of approximately $25 million post-merger [8][11] Product Development - FB-401 is a live biotherapeutic developed for inflammatory skin diseases, particularly atopic dermatitis [9][10] - There are approximately 17 million atopic dermatitis patients in the US, with a significant unmet need for effective treatments, especially in pediatrics [10][15] - The Phase 1-2A clinical data for FB-401 shows significant efficacy and a favorable safety profile in both pediatric and adult populations [10][12] Clinical Trials and Data - The Phase 1-2A trial included 10 adults and 20 pediatric patients, demonstrating a 50% improvement in atopic dermatitis scores with no adverse events reported [17][19] - The next Phase 2 study is expected to start by mid-2020, with data readouts anticipated in mid-2021 [12][20] Intellectual Property - Forte holds extensive intellectual property protection for FB-401, including four issued patents covering composition and use, with protection lasting until at least 2037 [10][20] Management and Advisory Team - The merged company will be led by Forte's current CEO, Paul Wagner, who has a strong background in advancing the company through critical milestones [8][9] - The scientific advisory board includes prominent figures in dermatology, enhancing the company's credibility and expertise in the field [13] Future Outlook - The merger is expected to create significant shareholder value by addressing unmet clinical needs in inflammatory skin diseases, particularly for pediatric patients [21][22] - The next 12 to 18 months are projected to be eventful with the publication of Phase 1-2A data and the anticipated start of the next trial [20] Additional Important Information - The call included a reminder about the forward-looking statements and associated risks, encouraging listeners to review SEC filings for more detailed information [3][4] - The merger aims to leverage the strengths of both companies to enhance the development and commercialization of innovative therapies for dermatological disorders [6][21]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------- ...

Tocagen® No One Should Die Of CancerTM A Cancer-Selective Gene Therapy Company Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking state ...

Tocagen® No One Should Die Of CancerTM A Cancer-Selective Gene Therapy Company Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking state ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 TOCAGEN INC. (Exact name of registrant as specified in its charter) Delaware 26 - 1243872 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38052 TOCAGEN INC. (Exact name of registrant as specified in its charter) Delaware 26 - 1243872 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |-----------------------------------------------------------------------------------------|--------------|---------------------------------- ...